Cosm Medical
Medical device company developing personalized 3D-printed pessaries (Gynethotics) for pelvic floor disorders, combining AI-driven design software and 3D printing.
- CEO / Founder
- Derek Sham
- Team Size
- 11-50
- Stage
- Growth Stage
- Total Funding
- $5.65M
- Latest Round
- Seed
- Key Investors
- Fusion Fund; iGan Partners; Spring Impact Capital; MaRS IAF; Telus Pollinator Fund; Archangel Fund; Scale Good Fund; Tech4Eva; World Intellectual Property Organization; Alliance of Angels
Technology & Products
Key Products
Gynethotics personalized pessaries (Ring with Support and Knob); Digital Gynecology Software (Clinic App for design/ordering, Patient App for education/symptom tracking); V-Caliper measurement tool; Post-surgical recovery devices (in development)
Technological Advantage
Combination of ultrasound imaging, AI-driven cloud design software, and 3D printing (biocompatible silicone) to create patient-specific gynecological prosthetics; proprietary digital gynecology platform; FDA 510(k) clearance and Health Canada medical device license.
Differentiation
Value Proposition
Patient-specific pessaries (Gynethotics) that replace trial-and-error fitting of standard pessaries, using AI, cloud software, and 3D printing to create custom-fit devices for pelvic organ prolapse and incontinence.
How They Differentiate
Offers FDA-cleared, personalized 3D-printed pessaries with AI-driven design software, replacing manual finger-measurement trial-and-error with data-driven personalization and millions of design configurations.
Market & Competition
Target Customers
Urogynecologists, pelvic health clinicians, and women with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence)
Industry Verticals
Women's Health / Femtech; Medical Devices; Pelvic Health
Competitors
FemTherapeutics; Uresta; traditional pessary manufacturers (CooperSurgical, Personal Medical Corp)
Growth & Milestones
Major Milestones
2017: Company founded; 2021: Won BASF Additive Manufacturing, RESI Digital, and TieQuest Toronto pitch competitions; 2022: $3.8M Seed round led by Fusion Fund; 2023: Pilot study published in Urogynecology journal; 2024: FDA 510(k) clearance for Gynethotics Pessaries (K231786); Health Canada medical device license obtained; 2025: Seed+ financing led by iGan Partners; 2026: Licensing and collaboration agreement with Duke Health and Mayo Clinic for post-surgical recovery devices
Notable Customers
Sinai Health Systems (Toronto); Toronto Pessary Clinic